China’s biotech industry has seen tremendous growth in recent years, with companies like Bloomage Biotech and Sinopharm leading the way in transforming healthcare. At the China International Consumer Products Expo (CICPE) held in south China's Hainan Province, companies showcased their latest products and technologies, demonstrating how they are advancing the field of biotech and improving patient outcomes.
Bloomage Biotech, known for its expertise in synthetic biology, particularly for producing hyaluronic acid, presented a range of biomaterials and biopharmaceuticals at the expo.
The company owns a set of homegrown key technologies in producing hyaluronic acid through microbial fermentation, which not only improves product quality but also significantly increases productivity and reduces production costs.
On April 11, Bloomage Biotech revealed its industry park in Haikou which includes a production line for stem cell culture medium. The line was a result of the company's strategic cooperation with Japan's Rohto Pharmaceutical and BioMimetics Sympathies thanks to Hainan's free trade port policies.
The localized product is expected to be launched in the second half of this year, the company said.
Meanwhile, China's COVID-19 vaccine producer Sinopharm showcased its expansion into the wellness industry. With about 100 units of product displayed at the expo, the company intend to tap into the blooming wellness market.
Sinopharm also launched its domestically developed inactivated rabies vaccine that intends to break the monopoly of foreign brands in the sector in the Chinese market.